Stockscreener 앱 받기
1.73
24.12%
-0.55
시간 외 거래:
1.66
-0.07
-4.05%
전일 마감가:
$2.28
열려 있는:
$2.27
하루 거래량:
133.51K
Relative Volume:
1.86
시가총액:
$2.64M
수익:
-
순이익/손실:
$-23.14M
주가수익비율:
-1.7076
EPS:
-1.0131
순현금흐름:
$-29.23M
1주 성능:
-46.93%
1개월 성능:
-75.79%
6개월 성능:
-77.74%
1년 성능:
-85.64%
1일 변동 폭
$1.59
$2.27
1주일 범위
$1.59
$3.25
52주 변동 폭
$1.59
$22.06
BiomX Inc Stock (PHGE) Company Profile
명칭
BiomX Inc
전화
972 7 23942377
주소
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
PHGE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHGE
BiomX Inc
|
1.73 | 3.48M | 0 | -23.14M | -29.23M | -1.0131 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
BiomX Inc Stock (PHGE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-04-15 | 개시 | Ladenburg Thalmann | Buy |
BiomX Inc 주식(PHGE)의 최신 뉴스
BiomX Discontinues Study and Files for Insolvency - TipRanks
BiomX Inc. Discontinues Phase 2b Study and Initiates Insolvency Proceedings - TradingView — Track All Markets
BiomX (NYSE: PHGE) subsidiary seeks insolvency as Phase 2b study ends, BX011 program retained - Stock Titan
BiomX Discontinues Phase 2b Trial for BX004 - The Globe and Mail
Healthy Upside Potential: BiomX Inc (PHGE) - setenews.com
BiomX Halts Phase 2b Trial Of BX004 In Cystic Fibrosis On High Rates Of Adverse Events - Nasdaq
Stocks Tumble As Bad News Hits Biotech And Energy Sectors - Finimize
BiomX Discontinues Phase 2b Clinical Trial for BX004 - TradingView
BiomX (PHGE) Halts Phase 2b Trial and Implements Cost-Saving Str - GuruFocus
BiomX announces discontinuation of phase 2b Bx004 trial following internal review - marketscreener.com
BiomX (NYSE American: PHGE) halts BX004 CF trial, to cut costs, weigh options - Stock Titan
BiomX discontinues phase 2b trial for BX004 - MSN
BiomX (PHGE) Price Target Increased by 964.52% to 168.30 - Nasdaq
BiomX (PHGE) Stock Analysis Report | Financials & Insights - Benzinga
Why BiomX Inc. stock could be top winner2025 Volatility Report & Precise Swing Trade Entry Alerts - Newser
How BiomX Inc. stock performs in high volatility marketsJuly 2025 Update & Daily Price Action Insights - Newser
How BiomX Inc. stock reacts to Fed tighteningJuly 2025 Update & AI Forecasted Entry/Exit Points - Newser
How BiomX Inc. stock compares with tech leadersJuly 2025 Review & Technical Pattern Alert System - Newser
How forex fluctuations impact BiomX Inc. stockWeekly Stock Recap & High Yield Equity Trading Tips - Newser
Is BiomX Inc. stock ideal for retirement investorsMarket Growth Report & Comprehensive Market Scan Reports - Newser
How BiomX Inc. stock behaves in tightening cyclesAnalyst Downgrade & Safe Entry Trade Signal Reports - Newser
BiomX provides update on BX004 Phase 2b trial in Cystic Fibrosis - MSN
BiomX announces 1-for-19 reverse stock split - MSN
H.C. Wainwright reiterates Buy rating on BiomX stock amid FDA queries By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy rating on BiomX stock amid FDA queries - Investing.com Canada
HC Wainwright Issues Optimistic Estimate for BiomX Earnings - Defense World
BiomX (NYSEAMERICAN:PHGE) Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World
BiomX (NYSEAMERICAN:PHGE) Price Target Raised to $26.00 at HC Wainwright - Defense World
HC Wainwright Forecasts Strong Price Appreciation for BiomX (NYSEAMERICAN:PHGE) Stock - Defense World
HC Wainwright Boosts BiomX (NYSEAMERICAN:PHGE) Price Target to $26.00 - Defense World
HC Wainwright & Co. Reiterates BiomX (PHGE) Buy Recommendation - Nasdaq
PHGE: HC Wainwright & Co. Reiterates Buy Rating with $26 PT | PH - GuruFocus
Why Is BiomX Stock Falling Today?BiomX (AMEX:PHGE) - Benzinga
BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review - Sahm
BiomX To Continue Cystic Fibrosis Study With Revised Dosing Of BX004; Data Expected In Q2, 2026 - Nasdaq
BiomX Says Working to Lift FDA Hold Concerning Nebulizer Device in Phase 2b Study of BX004 for Cystic Fibrosis - marketscreener.com
FDA Review Delays BiomX's (PHGE) Cystic Fibrosis Trial Progress - GuruFocus
BiomX Updates on Phase 2b Study for BX004 - TipRanks
BiomX Updates on FDA Clinical Hold and Study Progress - TradingView
BiomX (NYSE American: PHGE) DMC Backs BX004 Phase 2b Study, Topline Expected 2026 - Stock Titan
PHGE: HC Wainwright Raises Price Target for BiomX to $26.00 | PH - GuruFocus
HC Wainwright & Co. Maintains BiomX (PHGE) Buy Recommendation - Nasdaq
BiomX price target adjusted to $26 from $15 at H.C. Wainwright - TipRanks
BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis - Yahoo Finance
Stock splits calendar for: - Yahoo Finance Singapore
BiomX announces FDA feedback on development pathway for BX011 - MSN
BiomX Inc. Reports Q3 2025 Financial Results and Program Updates - MSN
BiomX Inc. Earnings Call: Progress Amid Challenges - MSN
Why BiomX Inc. stock stays undervaluedJuly 2025 Trends & Precise Swing Trade Entry Alerts - newser.com
BiomX Stock to Reverse Split on Tuesday, November 25th (NYSEAMERICAN:PHGE) - Defense World
BiomX Stock to Reverse Split on Tuesday, November 25th (NYSEMKT:PHGE) - Defense World
BiomX Inc (PHGE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
1.05%
자본화:
|
볼륨(24시간):